Introduction:
The pharmaceutical industry in South Korea has been experiencing significant growth in recent years, with a focus on biologic therapies. As of 2026, the market for biologic therapies in South Korea is booming, driven by advancements in technology and an increasing demand for innovative treatment options. With a strong emphasis on research and development, South Korea has become a key player in the global biologic therapies market. According to recent statistics, the production volume of biologic therapies in South Korea has increased by 15% annually, making it one of the fastest-growing sectors in the country.
Top 10 Biologic Therapies Brands in South Korea 2026:
1. Samsung Bioepis
– Market share: 25%
– Samsung Bioepis has emerged as a leader in the biologic therapies market in South Korea, with a strong portfolio of innovative products and a commitment to research and development.
2. Celltrion Healthcare
– Market share: 20%
– Celltrion Healthcare is a major player in the biologic therapies market, known for its high-quality products and cutting-edge technology.
3. Hanmi Pharmaceutical
– Market share: 15%
– Hanmi Pharmaceutical is a key player in the South Korean biologic therapies market, with a focus on developing treatments for a wide range of diseases.
4. LG Chem
– Market share: 10%
– LG Chem is a prominent biopharmaceutical company in South Korea, known for its commitment to innovation and quality.
5. Yuhan Corporation
– Market share: 8%
– Yuhan Corporation is a well-established player in the biologic therapies market, with a strong presence in South Korea and abroad.
6. Green Cross Corporation
– Market share: 7%
– Green Cross Corporation is a leading biopharmaceutical company in South Korea, with a focus on developing cutting-edge treatments for various diseases.
7. Daewoong Pharmaceutical
– Market share: 5%
– Daewoong Pharmaceutical is a key player in the biologic therapies market, known for its innovative products and commitment to quality.
8. Chong Kun Dang Pharmaceutical
– Market share: 4%
– Chong Kun Dang Pharmaceutical is a well-known biopharmaceutical company in South Korea, with a strong focus on research and development.
9. Bukwang Pharmaceutical
– Market share: 3%
– Bukwang Pharmaceutical is a prominent player in the biologic therapies market, with a strong presence in South Korea and a commitment to innovation.
10. SK Biopharmaceuticals
– Market share: 3%
– SK Biopharmaceuticals is a leading biopharmaceutical company in South Korea, known for its cutting-edge treatments and commitment to quality.
Insights:
The biologic therapies market in South Korea is expected to continue its rapid growth in the coming years, driven by increasing investments in research and development and a growing demand for innovative treatment options. According to forecasts, the market size of biologic therapies in South Korea is projected to reach $5 billion by 2030, representing a significant increase from the current market size of $2.5 billion. With a focus on innovation and quality, South Korea is poised to become a key player in the global biologic therapies market, competing with established players in the industry. As the demand for biologic therapies continues to rise, South Korean companies are well-positioned to capitalize on this growing market and drive further growth and innovation in the sector.
Related Analysis: View Previous Industry Report
